Xi Yun Zhang

机构：TauRx Pharmaceuticals (Singapore)

发表论文 10 篇 · 总被引 104 次 · h-index 3

代表论文

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma (2022 · Science Translational Medicine · 被引 39)
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma (2020 · Blood Cancer Journal · 被引 38)
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma (2020 · Experimental Hematology and Oncology · 被引 21)
Abstract 3137: Development of AT2604, a highly efficacious  ADC targeting alkaline phosphatases ALPP  and ALPPL2 (2024 · Cancer Research · 被引 2)
Selection of Fixed Effects in High-dimensional Generalized Linear Mixed Models (2023 · Acta Mathematica Sinica English Series · 被引 2)
Abstract 6741: AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload (2025 · Cancer Research · 被引 1)